血钠水平与肝硬化并发症发生的相关性研究
摘要
肝硬化失代偿期患者常发生血电解质紊乱，尤以低钠血症最为常见，严重时可诱发各种并发症。低钠血症的发生主要与自由水的清除减少有关。已有研究表明，低钠血症结合MELD评分可作为肝硬化患者较好的预后因素。本研究回顾性分析118例住院肝硬化患者并发症的发生与血钠水平的相关性，现将结果报道如下。
出处
《实用临床医药杂志》
CAS
2012年第23期137-137,149,共2页
Journal of Clinical Medicine in Practice
参考文献11
-
1Angeli P, Wong F, Watson H, et al. Hyponatremia in cir- rhosis: results of a patient population survey[J]. Hepatology, 2006, 44: 1535.
-
2Heuman D M, Abou- Assi S G, Habib A, et al. Persistent ascites and low serum .sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death [J]. Hepatology, 2004, 40: 802.
-
3中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14010
-
4陈灏珠.实用内科学[M].北京：人民卫生出版社,2002.1843.
-
5Forman L M, Lucey M R. Predicting the prognosis of chron- ic liver disease: an evolution from child to MELD[J]. Hepa- tology, 2001, 33: 473.
-
6徐晓光,蔡洪培.肝硬化低钠血症研究进展[J].中华消化杂志,2002,22(9):560-562. 被引量：95
-
7Jalan R, Hayes P C. Sodium handling in patients with well compenstateed cirrhosis is dependent on the severity of liver disease and portal pressure[J]. Gut, 2000, 46(4): 527.
-
8Gine P, Bed T, Bernardi M, et al. Hyponatremia in cirrho- sis: from pathogene sis 1o treatment[J]. Hepatology, 1998, 28". 851.
-
9Borroni G, Maggi A, Sangiovanni A, et al. Clinical relevance of hyponatraernia for the hospital outcome of cirrhotic patients [J]. Dig Liver Dis, 2000, 32: 605.
-
10Malinehoc M, Karnath P S, Gordon F D, et ah A model to predict Ix)or survival in patients undergoing transjugutar in- trahepatic portosystemic shunt [ J ]. Hepatology, 2000, 31 : 864.
二级参考文献10
-
1Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
-
2Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
-
3Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
-
4Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
-
5Bosch-Marce M,Jimenez W,Angeli P,et al.Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention[].Gastroenterology.1995
-
6Bosch-Marce M,Poo JL,Jimenez W,et al.Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention[].Journal of Pharmacology and Experimental Therapeutics.1999
-
7Borroni G,Maggi A,Sangiovanni A,et al.Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients[].Digestive and Liver Disease.2000
-
8Serradeil-Le-Gal C.Nonpeptide antagonists for vasopressin receptors.Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist[].Advances in Experimental Medicine and Biology.1998
-
9Yamamura Y,Ogawa H,Yamashita H,et al.Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist[].British Journal of Pharmacology.1992
-
10Gulberg V,Moller S,Henriksen JH,et al.Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure[].Gut.2000
共引文献14455
-
1刘洋.复方木鸡颗粒联合替诺福韦治疗代偿期乙型肝炎肝硬化患者的临床研究[J].慢性病学杂志,2019,0(12):1853-1854.
-
2李钊,黄宛香,李繁.乙型肝炎病毒感染肝硬化AST/ALT和LSM值与Child-Pugh分级及临床分期关系[J].热带医学杂志,2023,23(11):1593-1596.
-
3曾远松,黄柳春.茵郁芪灵汤联合恩替卡韦治疗慢性乙型肝炎的疗效观察[J].内蒙古中医药,2021,40(5):13-14. 被引量：2
-
4宫笑一,刘守华.代偿期乙肝肝硬化患者服用恩替卡韦对血清甲状腺激素水平的影响[J].中国农村卫生,2018,0(16):78-78.
-
5王雪艳,张旭东.甘草酸二铵对乙肝肝硬化患者TBIL、CⅣ及炎性因子的影响分析[J].医药论坛杂志,2021,42(16):7-10.
-
6欧阳福生.老年病毒性肝炎267例临床报告[J].山东大学学报（医学版）,2014,52(S01):83-84.
-
7潘晓华.阿德福韦酯联合拉米夫定治疗乙肝肝硬化患者80例8年的临床报道[J].世界最新医学信息文摘,2020(48):108-109.
-
8付振双.恩替卡韦治疗失代偿期慢性乙型病毒性肝炎肝硬化的临床研究[J].世界最新医学信息文摘,2020(2):150-150. 被引量：1
-
9陈新梅,陈昆迪.重型肝病转归与季节关系的探讨[J].医学信息,2018,31(A02):62-63.
-
10王同兴,于卫叶.联合检测血清PCⅢ,HA,LN对肝纤维化的诊断价值[J].医学信息（医学与计算机应用）,2016,29(28):217-218. 被引量：2
-
1陈柳莹,陆伦根.重视慢性肝病的病情评估[J].实用肝脏病杂志,2017,20(1):4-6. 被引量：4
-
2刘小珍,彭忠平.肝硬化并主动脉夹层2例临床分析[J].湖南中医药大学学报,2013,33(6):92-93. 被引量：1
-
3陆翠华.肝硬化并发症一:门静脉高压性上消化道出血[J].肝博士,2008(6):12-14. 被引量：1
-
4吴明瑶.肝硬化患者凝血功能指标对治疗和预后的指导作用[J].现代预防医学,2012,39(21):5754-5755. 被引量：1
-
5李川,吕文良,陈兰羽,杨广栋.针刺治疗肝硬化及其并发症研究进展[J].辽宁中医药大学学报,2012,14(8):269-271. 被引量：6
-
6李定国,范平.血管活性药在肝肾综合征中的作用[J].中华消化杂志,2004,24(11):703-704. 被引量：6
-
7张兵.女性肝硬化80例临床分析[J].中国医药指南,2013,11(18):111-112.
-
8张占卿.肝硬化并发症之一：门静脉高压症[J].世界感染杂志,2002,2(1):87-89.
-
9钟转华,陈渝萍.内毒素在肝硬化病情演变中的重要性及干预价值[J].河北医学,2010,16(1):25-27. 被引量：16
-
10刘玉芹,高菁,任可,庚及弟,朱玉梅,于秀辰.保元生血饮治疗肾性贫血的临床观察[J].北京中医药大学学报,1997,20(1):62-63. 被引量：7
